Synopsis The study is a phase 4 trial aiming to compare the safety and efficacy of bromfenac and dexamethasone in treating patients with anterior chamber inflammation post-cataract surgery. The patients were randomized into two groups and administered respective drugs in the form of ophthalmic solutions. Following this, they were assessed for several outcomes, such as best-corrected visual acuity (BCVA), macular thickness, and ocular comfort grading. Both drugs were found to be equally efficacious.
This “ Journal Watch ” discusses “ Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1% ” published in the journal Advances in Therapy, 2019. Authors – Coassin M, De Maria M, Mastrofilippo V, et al. What was the need for the study? Recently, the use of non-steroidal anti-inflammatory drugs (NSAIDs) as adjuvants or…
